bioAffinity Technologies (BIAF) Receivables - Other (2022 - 2026)

bioAffinity Technologies (BIAF) has reported Receivables - Other for 5 consecutive years, with $32497.0 the latest figure, recorded in Q1 2026.

• In Q1 2026, Receivables - Other rose 86.97% year-over-year to $32497.0; the TTM figure through Mar 2026 stood at $32497.0 (up 86.97% YoY), while the FY2025 annual figure was $26295.0, down 5.66% from the prior year.
• Receivables - Other improved to $32497.0 in Q1 2026 per BIAF's latest filing, from $26295.0 in the prior quarter.
• Across five years, Receivables - Other topped out at $119363.0 in Q2 2024 and bottomed at $4730.0 in Q3 2023.
• Historically, Receivables - Other has averaged $35014.8 across 5 years, with a median of $27508.5 in 2024.
• Annual changes were most pronounced in 2024 — Receivables - Other surged 940.02% — and 2025, when it slumped 83.65%.
• bioAffinity Technologies' Receivables - Other stood at $10489.0 in 2022, then soared by 181.75% to $29553.0 in 2023, then slipped by 5.68% to $27874.0 in 2024, then retreated by 5.66% to $26295.0 in 2025, then grew by 23.59% to $32497.0 in 2026.
• Business Quant data shows BIAF's Receivables - Other at $32497.0 in Q1 2026, $26295.0 in Q4 2025, and $27143.0 in Q3 2025.